I'm confused by this part...I thought we already h
Post# of 36537
In a new development, Generex has engaged with a potential partner in China and signed a LOI to develop the Ii-Key-SARS-CoV-2 vaccine for the Chinese market. The terms of the deal are currently being negotiated, however, when contracts are completed, and as outlined in the LOI, Generex will receive a $5 million upfront payment, and the Chinese partners will fund and conduct the clinical, manufacturing, laboratory, and regulatory work necessary to receive regulatory approval in China. Upon approval by the Chinese FDA, the LOI envisions manufacturing at least 200 million vaccine doses, with Generex receiving a minimum of $2 per dose of Ii-Key-SARS-CoV-2 vaccine.